December 06, 2025 17:30 ET | Source: Fulcrum Therapeutics, Inc. ― Clear dose-response observed, with a robust and clinically meaningful…
Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard…
Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment…
UDAIPUR, India, Nov. 12, 2025 /PRNewswire/ -- The Indian Institute of Management Udaipur (IIMU) successfully hosted the Startup Showcase & Pitch…
KARLSKOGA, Sweden, Nov. 11, 2025 /PRNewswire/ -- Last year, Cell Impact was awarded silver by EcoVadis. This year, the company has…
Sanjeev Luther, President and CEO to give an oral presentation and participate in a moderated panel discussion November 11, 2025…
KARLSKOGA, Sweden, Nov. 6, 2025 /PRNewswire/ -- Cell Impact and thyssenkrupp Automation Engineering have entered a Strategic Cooperation Agreement for Joint Market…
November 03, 2025 16:45 ET | Source: Fulcrum Therapeutics, Inc. ― Pociredir Phase 1b PIONEER Trial Data in Sickle Cell…
October 25, 2025 11:01 ET | Source: Cullinan Therapeutics, Inc. CLN-978 led to rapid and deep B cell depletion in…
Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable…